MARKET

OPK

OPK

Opko Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.020
-0.010
-0.33%
After Hours: 3.030 +0.01 +0.33% 18:37 05/25 EDT
OPEN
3.010
PREV CLOSE
3.030
HIGH
3.090
LOW
2.930
VOLUME
2.95M
TURNOVER
0
52 WEEK HIGH
5.25
52 WEEK LOW
2.430
MARKET CAP
2.06B
P/E (TTM)
-16.9663
1D
5D
1M
3M
1Y
5Y
Insider Buy: Opko Health
MT Newswires · 6d ago
OPKO Health stock gains; CEO buys shares worth ~$600K
OPKO Health (NASDAQ:OPK) stock gained over 4% on Tuesday after the firm disclosed that CEO and chairman Phillip Frost bought 200K shares at $2.95-$3.04 worth ~$600K. Frost Gamma Investments Trust, of
Seekingalpha · 05/17 19:55
Executives Buy Around $1.5M Of 4 Penny Stocks
US stock futures traded lower this morning on Thursday ahead of the producer price index. Investors, meanwhile, focused on some notable insider trades.
Benzinga · 05/12 11:32
OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
Zacks · 05/11 15:00
OPKO Health stock rises despite price target cut at Piper Sandler, Q1 revenue decline Y/Y
OPKO Health (NASDAQ:OPK) stock rose ~13% on May 10 following its Q1 results a day ago and announcing plans to acquire ModeX Therapeutics. However, Piper Sandler lowered its price target on
Seekingalpha · 05/10 16:34
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 05/10 16:01
Piper Sandler Adjusts OPKO Health's Price Target to $5 From $6, Reiterates Overweight Rating
MT Newswires · 05/10 05:03
OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates
OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 6.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 21:35
More
No Data
Learn about the latest financial forecast of OPK. Analyze the recent business situations of Opko Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
40.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OPK stock price target is 6.50 with a high estimate of 8.50 and a low estimate of 5.00.
High8.50
Average6.50
Low5.00
Current 3.020
EPS
Actual
Estimate
-0.08-0.05-0.010.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 338
Institutional Holdings: 206.26M
% Owned: 30.27%
Shares Outstanding: 681.46M
TypeInstitutionsShares
Increased
53
25.34M
New
34
3.69M
Decreased
70
19.55M
Sold Out
38
4.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.11%
Pharmaceuticals & Medical Research
+0.02%
Key Executives
Chairman/Chief Executive Officer/Director
Phillip Frost
President/Vice Chairman/Director
Elias Zerhouni
Vice Chairman/Chief Technology Officer/Director
Jane Hsiao
Chief Financial Officer/Senior Vice President/Chief Accounting Officer/Treasurer
Adam Logal
Corporate Executive/Director
Jon Cohen
Corporate Executive
Charles Bishop
Corporate Executive
Tony Cruz
Corporate Executive
Geoff Monk
Corporate Executive
Katherine Stueland
Executive Vice President/Director
Steven Rubin
Other/Director
Gary Nabel
Director
Alexis Borisy
Independent Director
Richard Krasno
Independent Director
Prem Lachman
Independent Director
Roger Medel
Independent Director
John Paganelli
Independent Director
Richard Pfenniger
Independent Director
Alice Yu
No Data
No Data
About OPK
OPKO Health, Inc. is a healthcare company. Its segments include Diagnostics and Pharmaceutical. The Pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain. The Diagnostics segment consists of the clinical laboratory operations of Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health) and GeneDx. Its Pharmaceutical Business have one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Oxyntomodulin, Biologics, Factor VIIa -CTP, hGH-CTP. It also owns an active pharmaceutical ingredients (APIs) manufacturer in Israel through its subsidiary FineTech Pharmaceutical, Ltd.

Webull offers kinds of Opko Health Inc. stock information, including NASDAQ:OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.